SEC Form SC 13G/A filed by Histogen Inc. (Amendment)

$HSTO
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $HSTO alert in real time by email
SC 13G/A 1 ea155266-13ga1intra_histogen.htm AMENDMENT NO. 1 TO SCHEDULE 13G

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 1)*

 

Histogen Inc.

 

(Name of Issuer)

 

Common Stock, $0.0001 par value per share

 

(Title of Class of Securities)

 

43358Y103

 

(CUSIP Number)

 

December 31, 2021

 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

a.Rule 13d-1(b)
b.☒ Rule 13d-1(c)
c.☐ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

Page 1 of 6

 

 

CUSIP No. 43358Y103  

 

1. Names of Reporting Persons.
   
  Mitchell P. Kopin
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a) ☐
  (b)
3. SEC Use Only
     
4. Citizenship or Place of Organization United States of America
     

Number of

Shares Beneficially

Owned by Each

Reporting

Person With:

5. Sole Voting Power 0
     
6. Shared Voting Power 5,282,710
     
7. Sole Dispositive Power 0
     
8. Shared Dispositive Power 5,282,710
       
9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,710 (see Item 4)
     
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
     
11. Percent of Class Represented by Amount in Row (9) 9.99% (see Item 4)
     
12. Type of Reporting Person (See Instructions)  
     
  IN; HC  

 

Page 2 of 6

 

 

CUSIP No. 43358Y103  

 

1. Names of Reporting Persons.
   
  Daniel B. Asher
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a)
  (b)
3. SEC Use Only
     
4. Citizenship or Place of Organization United States of America
     

Number of

Shares Beneficially

Owned by Each

Reporting

Person With:

5. Sole Voting Power 0
     
6. Shared Voting Power 5,282,710
     
7. Sole Dispositive Power 0
     
8. Shared Dispositive Power 5,282,710
       
9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,710 (see Item 4)
     
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
     
11. Percent of Class Represented by Amount in Row (9) 9.99% (see Item 4)
     
12. Type of Reporting Person (See Instructions)  
     
  IN; HC  

 

Page 3 of 6

 

 

CUSIP No. 43358Y103

 

1. Names of Reporting Persons.
   
  Intracoastal Capital LLC
2. Check the Appropriate Box if a Member of a Group (See Instructions)
   
  (a) ☐
  (b) ☐
3. SEC Use Only
     
4. Citizenship or Place of Organization Delaware
     

Number of

Shares Beneficially

Owned by Each

Reporting

Person With:

5. Sole Voting Power 0
     
6. Shared Voting Power 5,282,710
     
7. Sole Dispositive Power 0
     
8. Shared Dispositive Power 5,282,710
       
9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,710 (see Item 4)
     
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
     
11. Percent of Class Represented by Amount in Row (9) 9.99% (see Item 4)
     
12. Type of Reporting Person (See Instructions)  
     
  OO  

 

Page 4 of 6

 

 

This Amendment No. 1 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on January 8, 2021 (the “Schedule 13G”).

 

Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

 

Item 4. Ownership.

 

(a) and (b):

 

As of the close of business on December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 5,282,710 shares of Common Stock, which consisted of (i) 2,352,942 shares of Common Stock held by Intracoastal, (ii) 2,352,942 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”) and (iii) 576,826 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), and all such shares of Common Stock represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 49,950,212 shares of Common Stock outstanding as of December 21, 2021 as reported by the Issuer, plus (2) 2,352,942 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (3) 576,826 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 423,174 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock and (II) 1,454,552 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 7,160,436 shares of Common Stock.

 

(c) Number of shares as to which each Reporting Person has:

 

(i) Sole power to vote or to direct the vote: 0.

 

(ii) Shared power to vote or to direct the vote: 5,282,710.

 

(iii) Sole power to dispose or to direct the disposition of 0.

 

(iv) Shared power to dispose or to direct the disposition of 5,282,710.

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

Page 5 of 6

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 11, 2022

 

  /s/ Mitchell P. Kopin
  Mitchell P. Kopin
   
  /s/ Daniel B. Asher
  Daniel B. Asher

 

  Intracoastal Capital LLC
     
  By: /s/ Mitchell P. Kopin
    Mitchell P. Kopin, Manager

 

Page 6 of 6

 

Get the next $HSTO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HSTO

DatePrice TargetRatingAnalyst
8/30/2021$2.40Buy
HC Wainwright & Co.
More analyst ratings

$HSTO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Histogen Announces Second Adjournment of Special Meeting of Stockholders

    Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO), today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, January 4, 2024 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The Special Meeting, which will be reconvened for a final time on January 4, 2024, will continue to be held v

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Histogen Announces Adjournment of Special Meeting of Stockholders

    SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC:HSTO) today announced that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both proposals described in its definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "SEC") on October 18, 2023 (the "Proxy Statement"). The reconvened Special Meeting on December 14, 2023 will continue to be held via live webcast at www.virtualshareholdermeeting.com/HSTO2023SM. In addition, the record date for determining stockholders entitled to vote at the Special Meeting will remain the close of business on Octob

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Histogen Announces Board Approval of Complete Liquidation and Dissolution

    SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution ("Plan of Dissolution") that would include the distribution of remaining cash to stockholders following an orderly wind down of the company's operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of Septem

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HSTO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HSTO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HSTO
SEC Filings

See more

$HSTO
Leadership Updates

Live Leadership Updates

See more
  • Histogen Hires Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer

    SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the appointment of Alfred P. Spada Ph.D. as Executive Vice President and Chief Scientific Officer. "We are very excited about Dr. Spada joining our management team.  Dr. Spada is a world expert in both the biology of apoptosis and the chemistry of designing potent caspase inhibitors," said Steven J. Mento Ph.D., Executive Chairman and Interim President and Chief E

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

    Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t

    $CVM
    $HSTO
    $TXMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Orhub's Ryan Fernan Becomes Head Of Pur Biologics, Leading Regenerative Therapeutic Efforts

    A proven industry leader and executive, Ryan Fernan, will help ORHub advance Ortho-Spine technology beyond current limitations.IRVINE, CA / ACCESSWIRE / July 27, 2022 / ORHub, Inc. (OTC:ORHB) officially kicks off the acquisition of PUR Biologics ("PUR") with the appointment of Ryan Fernan as the Head of PUR Biologics. An ORHub biotech company, PUR Biologics is focused on delivering next generation regenerative biologic products to address degenerative musculoskeletal diseases.Mr. Fernan, brings direct access to a broad industry network with a proven track record of over 18 years in the medical device and biotechnology industry. Recognized as a frontrunner in sales and product development, Mr

    $BAX
    $HSTO
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

$HSTO
Financials

Live finance-specific insights

See more
  • Histogen Reports Year-End 2022 Results and Provides Business Update

    SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function, today reported financial results for the year ended December 31, 2022, and provided an update on its pipeline and other corporate developments. "Our team is very excited about the new direction of the company. We remain focused on the development of emricasan as a potential treatment for acute bacterial skin and skin structure infections (ABSSSI), including those related to methicillin res

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

    SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus ("MRSA") and evaluating our caspase-1 inh

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

    Closed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments. "We continue to focus on execution of IND enabling activities for HST 004 in spinal disc regeneration, exploration of testing emricasan in ani

    $HSTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

$HSTO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more